Subventions et des contributions :

Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2020-2021)

According to the Canadian Cancer Society, the 5-year survival rate for oral cancer is onlyx000D
63%. Each year 4,600 new cases in Canada and 300,000 cases worldwide are identified andx000D
on average, half of the patients die within 5 years of diagnosis. The recurrence rate of oralx000D
cancer after surgery is high at 20%. Therefore, there is a critical need for new technology thatx000D
can improve the early detection and treatment of oral cancer. In this project, a new point-ofcarex000D
cancer imaging device based on multiphoton imaging will be developed to provide highresolutionx000D
imaging of oral mucosa lesions in vivo and in real-time. Multiphoton imaging canx000D
provide visualization of important biomarkers for cancer detection: the morphological changesx000D
of tumor cells and nuclei, and the density and ordering of the underlying collagen fibers whichx000D
facilitates the progression and invasion of tumor cells. It has been demonstrated to be veryx000D
successful in pre-clinical cancer studies on animal models. Translating multiphoton imagingx000D
into clinical applications is just beginning. Challenges include handling femtosecond plusesx000D
and limited signal to noise ratio. We will address those challenges and design a portablex000D
multiphoton system with a handheld probe for performing in vivo imaging of the oral mucosa.x000D
In vivo imaging on patients will be carried out to evaluate the device for guided biopsy andx000D
tumor margin detection. The new technology can improve cancer management by real-timex000D
assessment of tumor noninvasively and guiding decisions on when and where to takex000D
biopsies for early cancer detection.